سعر جونال-اف 300 وحدة دولية قلم 2024

English text not available for this section.

• Adult women: anovulation (including PCOS) unresponsive to clomiphene citrate; stimulation of multifollicular development for ART (IVF, GIFT, ZIFT); with an LH preparation for follicular development in severe LH and FSH deficiency. Adult men: stimulation of spermatogenesis in congenital or acquired hypogonadotrophic hypogonadism with hCG.Population: AdultsEuropean Medicines Agency (EPAR product information)
• Induction of ovulation and pregnancy in oligo-anovulatory women whose infertility is functional and not due to primary ovarian failure; development of multiple follicles in ovulatory women as part of an ART cycle.Population: Adult womenDailyMed (U.S. National Library of Medicine)

• Women - very common: headache, ovarian cysts, injection-site reactions; common: abdominal pain/distension, nausea, vomiting, diarrhoea, mild or moderate OHSS; uncommon: severe OHSS; very rare: hypersensitivity/anaphylaxis, thromboembolism, asthma exacerbation. Men - common: acne, gynaecomastia, varicocele, weight gain; very common: injection-site reactions.International label, same formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to follitropin alfa or excipients; tumours of the hypothalamus or pituitary; ovarian enlargement or cyst not due to PCOS; gynaecological haemorrhage of unknown origin; ovarian, uterine or mammary carcinoma; and when an effective response cannot be obtained (primary ovarian failure, sexual-organ malformations or uterine fibroids incompatible with pregnancy, primary testicular insufficiency).International label, same formulation · European Medicines Agency (EPAR product information)
• Women with prior hypersensitivity to recombinant FSH, high FSH indicating primary gonadal failure, uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary), sex-hormone-dependent reproductive tumours, pituitary or hypothalamic tumours, abnormal uterine bleeding of undetermined origin, or ovarian cyst/enlargement not due to PCOS.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ovarian hyperstimulation syndrome (OHSS) can be severe and progress rapidly; risk factors include young age, low body mass, PCOS, high gonadotropin doses, high or rapidly rising estradiol and many follicles; if signs occur, withhold hCG and advise avoiding coitus or using barrier contraception for at least 4 days; follow patients for at least 2 weeks after hCG.International label, same formulation · European Medicines Agency (EPAR product information)
• Increased risk of multiple pregnancy, pregnancy loss and ectopic pregnancy; possible aggravation of thromboembolic events in women with risk factors; patients with porphyria should be closely monitored; evaluate hypothyroidism, adrenocortical deficiency and hyperprolactinaemia before treatment.International label, same formulation · European Medicines Agency (EPAR product information)

• hCG, clomiphene citrate (other ovulation stimulants)May potentiate the follicular response.European Medicines Agency (EPAR product information)
• GnRH agonists or antagonistsPituitary desensitisation may increase the GONAL-f dose needed for an adequate ovarian response.European Medicines Agency (EPAR product information)

• No indication for use during pregnancy; limited data (<300 pregnancy outcomes) show no malformative or feto/neonatal toxicity, but a teratogenic effect cannot be excluded.International label, same formulation · European Medicines Agency (EPAR product information)
• Not indicated in pregnant women; verify a negative pregnancy test before use; miscarriage risk is increased with gonadotropin-assisted pregnancy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not indicated during breast-feeding.International label, same formulation · European Medicines Agency (EPAR product information)

• Follitropin alfa: FSH stimulates the development of ovarian follicles; with LH it supports follicle development and maturation (EU SmPC 5.1).